Patents by Inventor Travis Wilson

Travis Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190022165
    Abstract: The disclosure provides methods of preventing or treating pulmonary arterial hypertension (PAH) in a mammalian subject, reducing risk factors associated with PAH, and/or reducing the likelihood or severity of PAH. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: March 2, 2017
    Publication date: January 24, 2019
    Inventor: D. Travis WILSON
  • Publication number: 20190000915
    Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.
    Type: Application
    Filed: January 29, 2018
    Publication date: January 3, 2019
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Publication number: 20180362579
    Abstract: The disclosure provides compositions and methods relating to aromatic-cationic peptides. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. For example, the peptides may be administered to subjects in need of a mitochondrial-targeted antioxidant.
    Type: Application
    Filed: January 9, 2018
    Publication date: December 20, 2018
    Inventors: D. Travis WILSON, Marc W. ANDERSEN, Elizabeth MEAD
  • Publication number: 20180360906
    Abstract: The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 20, 2018
    Inventors: D. Travis WILSON, Robert A. KLONER
  • Publication number: 20180354991
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of Gramicidin S peptidyl conjugates (and/or derivatives, analogues, or pharmaceutically acceptable salts thereof), or imidazole-substituted fatty acids (and/or derivatives, analogues, or pharmaceutically acceptable salts thereof), alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to imidazole-substituted fatty acids or Gramicidin S peptidyl conjugates of the present technology and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2?,6?-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: December 21, 2017
    Publication date: December 13, 2018
    Inventor: D. Travis Wilson
  • Publication number: 20180344814
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants or analogues of GLP-1, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2?6?-Dmt-Lys-Phe-NH2).
    Type: Application
    Filed: December 21, 2017
    Publication date: December 6, 2018
    Inventor: D. Travis Wilson
  • Publication number: 20180344797
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.
    Type: Application
    Filed: December 20, 2017
    Publication date: December 6, 2018
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey
  • Publication number: 20180339012
    Abstract: Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and in some applications, a second active agent chemically linked to the peptide, to subjects in need thereof.
    Type: Application
    Filed: December 20, 2017
    Publication date: November 29, 2018
    Inventors: D. Travis Wilson, Mark Bamberger, Brian Blakey, Marc W. Andersen
  • Publication number: 20180327450
    Abstract: The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: December 13, 2017
    Publication date: November 15, 2018
    Inventors: D. Travis Wilson, Lilach O. Lerman, Stephen C. Textor
  • Publication number: 20180296630
    Abstract: The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. More specifically, the disclosure provides a composition for preventing, treating, or ameliorating the symptoms of diabetic macular edema in a mammalian subject in need thereof, comprising: a therapeutically effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 29, 2017
    Publication date: October 18, 2018
    Inventors: D. Travis Wilson, K. George Mooney, Peter J. Oates
  • Publication number: 20180228864
    Abstract: This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is D-Arg-2 6-Dmt-Lys-Phe-NH2 (SS-31).
    Type: Application
    Filed: September 27, 2017
    Publication date: August 16, 2018
    Inventors: Kenneth Borow, D. Travis Wilson
  • Patent number: 10047395
    Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: August 14, 2018
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Publication number: 20180207225
    Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 26, 2018
    Inventor: D. Travis Wilson
  • Publication number: 20180193405
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: August 20, 2015
    Publication date: July 12, 2018
    Inventor: D. Travis Wilson
  • Patent number: 9988422
    Abstract: The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 5, 2018
    Assignees: STEALTH BIOTHERAPEUTICS CORP, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: D. Travis Wilson, Lilach O. Lerman, Stephen C. Textor
  • Publication number: 20180147251
    Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
    Type: Application
    Filed: June 19, 2017
    Publication date: May 31, 2018
    Inventors: D. Travis Wilson, Mark Bamberger
  • Publication number: 20180117112
    Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.
    Type: Application
    Filed: June 14, 2017
    Publication date: May 3, 2018
    Inventors: Kenneth Borow, D. Travis Wilson
  • Patent number: 9943563
    Abstract: The present technology provides methods of preventing or treating vitiligo. The methods provide administering aromatic-cationic peptides in effective amounts to treat or ameliorate melanocyte degeneration such as that found in a subject suffering from, or predisposed to vitiligo. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for vitiligo, an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates to the treatment, amelioration or prevention of vitiligo in mammals or mammalian cells, through administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2?,6?-Dmt-Lys-Phe-NH2.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: April 17, 2018
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Patent number: 9905226
    Abstract: A voice command definition file (VCDF) declaratively defines voice commands for an application. For example, the VCDF may include definitions for: voice commands; one or more phrases/utterances that may be said to execute each of the commands; a navigation location to navigate to within the application (e.g. a page); phrase lists containing items that may be used as a parameter in a voice command; examples; feedback; and the like. A user may say a single utterance to launch the application, navigate to the associated location of the command and execute the command. The VCDF may define multiple ways to listen for a particular command. The VCDF may be edited/defined by a user and may include a user friendly name for an application. A speech engine loads the VCDF for use such that it may recognize the commands associated with an application. The definitions may be updated during runtime.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: February 27, 2018
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: F. Avery Bishop, Travis Wilson, Robert Chambers, Robert Brown
  • Publication number: 20180044378
    Abstract: The present technology provides methods of generating the peptides, and pharmaceutically acceptable salts of the peptides and intermediates thereof. In some embodiments, the peptide is D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: March 7, 2016
    Publication date: February 15, 2018
    Inventors: Scott DUNCAN, D. Travis WILSON